- Supporting Patients With Schizophrenia in the Era of COVID-19
-
Kim SW
- KMID: 2522030
- Korean J Schizophr Res.
- 2021 Oct;24(2):45-51.
- doi: 10.16946/kjsr.2021.24.2.45
The coronavirus disease 2019 (COVID-19) pandemic has drastically impacted our society and health care system. People with schizophrenia are more vulnerable to this burden of illness and related societal changes.... -
- CITED
-
- Close
- SHARE
-
- Close
- Association of the First Antipsychotic Treatment Duration With the Re-Initiation of Treatment in Schizophrenia: A National Health Insurance Data-Based Study
-
Song M, Lee J, Kim H, Ahn S, Choi YJ, Jo YT, Joo SW
- KMID: 2522032
- Korean J Schizophr Res.
- 2021 Oct;24(2):60-67.
- doi: 10.16946/kjsr.2021.24.2.60
Objectives: The optimal duration of maintenance treatment for patients with first-episode schizophrenia (FES) remains unclear. We examined the first antipsychotic treatment duration and its association with re-initiation of treatment using... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Delayed Clozapine Initiation on Acute Treatment Response in Treatment-Resistant Schizophrenia
-
Yang SY, Choi JK, Park S, Park J
- KMID: 2522031
- Korean J Schizophr Res.
- 2021 Oct;24(2):52-59.
- doi: 10.16946/kjsr.2021.24.2.52
Objectives: Recent studies have reported that delayed initiation of clozapine can affect clinical response in patients with treatment-resistant schizophrenia (TRS). This study aimed to explore the relationship between delayed initiation... -
- CITED
-
- Close
- SHARE
-
- Close
